ACONW ACLARION INC C/WTS (TO PUR COM)
- 0.0430
- -0.0153-26.28%
ACLARION INC C/WTS (TO PUR COM) News
Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain
LIFEHAB is a randomized controlled trial in Norway comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation Norway is a single-payer national health insurance system LIFEHAB is targeting
Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs
Confirms predictive value of Nociscan for identifying painful discs. Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting Nociscan
Aclarion Announces Closing of $3.0 Million Public Offering
BROOMFIELD, CO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary
Aclarion Announces Pricing of $3.0 Million Public Offering
BROOMFIELD, CO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary
Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership
Company is initiating its pivotal multicenter, prospective, randomized CLARITY trial to build on clinical evidence demonstrating superior surgical outcomes when Nociscan is utilized in surgical decisi
Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD
Dr. Uribe is Chief of the Division of Spinal Disorders, Volker K. H. Sonntag Chair of Spine Research, and Vice Chairman of Neurosurgery at Barrow Neurological Institute.
Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution
Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine This new product release expands accessibility of Nociscan on the worldwide MR market Builds on pre
Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times
Aclarion Announces Reverse Stock Split
BROOMFIELD, CO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary
Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams
Pace of Nociscan orders accelerated 2.5x for the last 250 scans compared to the first 250 scans Further acceleration of scan volumes expected as MRIs are activated for the recently completed panel of 10 Key Opinion
Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption
Recruitment of a panel of leading KOL surgeons who believe Nociscan can improve the diagnosis and treatment of discogenic low back pain is a critical step to establishing Nociscan as standard of care.
Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD
Dr. Hartl is the Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at the Weill Cornell Brain and Spine Center in New York, and the co-director of New York-Presbyterian
Aclarion Presents at the NIH HEAL Initiative Fall Meeting
The Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, is funding ground-breaking low back pain research. The Back Pain Consortium (BACPAC) Research Program, a recipient of the NIH
Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth Facility, to Bring Nociscan Technology to Denver
Porter Hospital Becomes First Facility in Denver to Give Chronic Low Back Pain Patients Access to Revolutionary Nociscan Technology That Measures Biomarkers to Pinpoint the Source of Pain George Frey, MD Becomes
Aclarion Announces Nociscan Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting
Nociscan cost-effectiveness abstract poster highlights dominance over provocative discography. The 45th Annual Society for Medical Decision Making (SMDM) Meeting is being held October 22-25, 2023. Founded
Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan
Partnership aims to include Aclarion's Nociscan surgical decisioning technology within ATEC's AlphaInformatiX platform to better inform spine surgery ATEC is a medical device company dedicated to revolutionizing the
Aclarion Provides Updated Investor Presentation and Corporate Update
Aclarion is steadily executing on a proven path toward standard of care. Ten prominent Key Opinion Leader (KOL) surgeons have formally engaged to partner with the company to drive market traction and reimbursement.
Aclarion Announces New Commercial Engagement With The Imaging Center, Grand Rapids, MI
BROOMFIELD, CO, June 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary
Aclarion Announces Statistically Significant Nociscan Cost-Effectiveness Abstract Presented at ISASS Annual Meeting
Aclarion Announces New Engagement With The London Clinic and London Spine Clinic
The London Clinic is the UK's most renowned independent, private hospital, established 1932. The London Spine Clinic is first specialist spinal unit established in England, 1997. The London Clinic wil
Analysis
Price Target
No Data
